ReviewJournal of neuro-oncology2010
Intracranial meningiomas of atypical (WHO grade II) histology.
Review in Journal of neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prediction of Meningioma WHO Grade Using PET Findings: A Systematic Review and Meta-Analysis.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2021Pooled it
- Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review.Neuro-oncology · 2014Pooled it
- Extent of resection and survival outcomes in World Health Organization grade II meningiomas.Journal of neuro-oncology · 2021Trial
- High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.International journal of radiation oncology, biology, physics · 2020Trial
- Trial
- Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.Journal of neuro-oncology · 2012Trial
- Integration of ⁶⁸Ga-DOTA-TOC PET/CT into radiotherapy planning for intracranial meningiomas: A precision-imaging approach to tumor delineation.Annals of nuclear medicine · 2026Observational
- Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67.Acta neurochirurgica · 2025Article
- Recurrence of Resected Skull Base Meningiomas during Long-term Follow-up: Incidence and Predisposing Factors.Journal of neurological surgery. Part B, Skull base · 2025Article
- Unveiling Biomarkers in Head and Neck Squamous Cell Carcinoma through Bioinformatics: The Role ofInternational journal of molecular sciences · 2024Article
- The Impact of Molecular and Genetic Analysis on the Treatment of Patients with Atypical Meningiomas.Diagnostics (Basel, Switzerland) · 2024Review
- Descriptive epidemiology of 30,223 histopathologically confirmed meningiomas in France: 2006-2015.Acta neurochirurgica · 2024Article
- Article
- Simpson's Grading Scale for WHO Grade I Meningioma Resection in the Modern Neurosurgical Era: Are We Really Asking the Right Question?Journal of neurological surgery. Part B, Skull base · 2024Article
- Meningioma recurrence: Time for an online prediction tool?Surgical neurology international · 2024Review
- Analysis of the efficacy of microdissection of paravebous sinus meningiomas invading large venous sinuses.BMC surgery · 2023Article
- De Novo Skull Base Atypical Meningioma: Incidence and Outcome.Journal of neurological surgery. Part B, Skull base · 2023Article
- Genomic Landscape of Meningiomas.Advances in experimental medicine and biology · 2023Article
- Meningioma and Other Meningeal Tumors.Advances in experimental medicine and biology · 2023Article
- Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018.Journal of neuro-oncology · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical (WHO grade II) meningiomas occupy an intermediate risk group between benign (WHO grade I) and anaplastic (WHO grade III) meningiomas. Although grade II meningiomas have traditionally been recognized in only about 5% of cases, after changes in diagnostic criteria with the current 2007 WHO standards, they now comprise approximately 20-35% of all meningiomas. Given the magnitude of this change, much work is now needed to solidify the adoption of these standards, to render inter-observer and inter-institutional comparisons more uniform, and to more carefully define the incidence of grade II histology. However, it is clear that they carry a several-fold increased risk of recurrence, as well as an increased rate of mortality. We will discuss the definition, diagnosis, and treatment of patients with atypical meningioma; review the current phase II cooperative trials; and draw attention to some questions timely for pre-clinical and clinical research.
Indexed as
Identifiers
20740303What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.